An analysis of detection bias and proposed corrections in the study of estrogens and endometrial cancer.

S. Greenland,R. Neutra

DOI: https://doi.org/10.1016/0021-9681(81)90002-3

Journal of Chronic Diseases

Abstract:

What problem does this paper attempt to address?

Regulation of the stress response by ceramide.

G. Dbaibo

DOI: https://doi.org/10.1042/BST0250557

1997-05-01

Biochemical Society Transactions

Abstract:
New Transcriptomic Biomarkers for Detection of the Recombinant Human Erythropoietin (rHuEPO) MirCERA in Horses

Benoit Loup,François André,Nicolas Leuenberger,Alexandre Marchand,Agnès Barnabé,Vivian Delcourt,Patrice Garcia,Marie‐Agnès Popot,Ludovic Bailly‐Chouriberry

DOI: https://doi.org/10.1002/dta.3812

2024-09-27

Drug Testing and Analysis

Abstract:ALAS2, CA1, and SLC4A1 mRNAs have previously been described as blood doping biomarkers in humans. A qPCR method was developed to detect the equine orthologues in equine whole blood, and their upregulation was observed after administration of a single dose of MirCERA. This work provides proof of concept for the use of ALAS2, CA1, and SLC4A1 in horses for doping control as an indirect method of detecting rHuEPO MirCERA abuse by monitoring transcriptomic biomarkers. Detection and monitoring of biomarkers related to doping is particularly suitable for the development of analytical strategies dedicated to indirect detection of banned substances. Previous studies in horses have already allowed the investigation of transcriptomic biomarkers in equine blood associated with reGH and rHuEPO administrations. Our most recent developments continue to focus on the discovery and monitoring of transcriptomic biomarkers for the control of ESAs, and a collaborative study with WADA‐accredited doping control laboratories has recently been initiated to conduct a pilot study. In humans, three mRNAs (ALAS2, CA1, and SLC4A1) were previously observed to be differentially expressed after blood doping and were associated with immature red blood cells, the so‐called circulating reticulocytes. In horses, circulating reticulocytes are rarely observed even after rHuEPO administration. With the improved primers that detect the equine orthologues of the human mRNAs from the ALAS2, CA1, and SLC4A1 genes, we can now report the first evidence of the detection of the three biomarkers in equine blood. In addition, an upregulation of the mRNA levels of the three genes was observed after analysis of blood samples collected from MirCERA‐treated animals, with kinetics similar to those previously documented in humans. Our data suggest that ALAS2 and CA1 are promising indirect biomarkers for the detection of recombinant EPO abuse in horses, as observed in humans.

pharmacology & pharmacy,biochemical research methods,chemistry, analytical
A hybrid approach for mismatch data reduction in datasets and guide data mining

R. Dhanalakshmi,T. Sethukarasi

DOI: https://doi.org/10.1007/s10586-017-1137-4

2017-09-04

Cluster Computing

Abstract:
An enhanced label-free proteomics approach for deep-diving into equine plasma proteome, including the discovery of protein biomarkers for strenuous exercise

Hiu Wing Cheung,Kin-Sing Wong,Ning Sum To,Terence S M Wan,Emmie N M Ho

DOI: https://doi.org/10.1002/dta.3606

Abstract:Plasma proteins have been a valuable source of biomarkers for clinical uses and for monitoring of the illicit use of prohibited substances or practices in equine sports. We have previously reported the first use of label-free proteomics in profiling equine plasma proteome. This study aimed to refine the method by systematically evaluating various plasma fractionation methods and the use of narrower precursor mass ranges in data-independent acquisition (DIA) mass spectrometry (MS). Tandem fractionations of equine plasma with octanoic acid precipitation followed by solid-phase extraction (SPE) with C4 cartridges provided the largest increase in the number of new proteins identified. The use of two narrow precursor mass ranges of m/z 400-600 and 600-800 in DIA not only identified most proteins detectable by using a single mass range of m/z 350-1500 but also identified ~27% more proteins. The improved method was applied to analyse the plasma proteome of 'postrace' samples which, unlike other samples, had been collected from racehorses soon after racing. Multivariate data analysis has identified upregulation of 14 proteins and downregulation of six proteins in postrace plasma compared with the non-postrace plasma samples. Literature review of these proteins has provided evidence of exercise-induced haemolysis and changes in antioxidant enzyme activities, kinin system, insulin signalling and energy metabolism after strenuous exercise. The improved method has enabled a deeper profiling of the equine plasma proteome and identified the proteins associated with normal physiological changes after racing which are potential confounding factors in the development of a biomarker approach for doping control.
Hemicellulose composition of dietary fiber of milled rice and rice bran.

R. R. Mod,E. J. Conkerton,R. Ory,F. L. Normand

DOI: https://doi.org/10.1021/JF60219A062

IF: 6.1

1978-05-01

Journal of Agricultural and Food Chemistry

Abstract:
Screening and confirmatory analysis of recombinant human erythropoietin for racing camels' doping control

Vivian Delcourt,Patrice Garcia,Benjamin Chabot,Benoit Loup,Pierre Remy,Marie-Agnès Popot,Ludovic Bailly-Chouriberry

DOI: https://doi.org/10.1002/dta.2772

Abstract:Recombinant human erythropoietin (rHuEPO) belongs to the therapeutic class of erythropoiesis stimulating agents (ESAs) due to its implication in the creation pathway of red blood cells and thus enhancement of oxygenation. Because of this bioactivity, rHuEPO has been considered as a major doping agent in sports competitions for decades. Over the years, doping control laboratories designed several analytical strategies applied to human and animal samples to highlight any misuse. Even though multiple analytical approaches have been reported, none has yet been dedicated to racing camels. Here, we describe an analytical strategy to test camel plasma samples at screening using an ELISA assay and a targeted nano-liquid chromatography-high-resolution tandem mass spectrometry for confirmatory analysis. The method was validated and has been successfully applied to post-race samples, allowing the detection of a positive case of rHuEPO administration.
3-Methoxytyrosine as an indicator of dopaminergic manipulation in equine plasma

Bethany Keen,Adam Cawley,Brian Reedy,Glenys Noble,Jaymie Loy,Shanlin Fu

DOI: https://doi.org/10.1016/j.jchromb.2023.123652

2023-04-01

Abstract:The use of catechol-O-methyltransferase inhibitors may mask doping agents, primarily levodopa, administered to racehorses and prolong the stimulating effects of dopaminergic compounds such as dopamine. It is known that 3-methoxytyramine is a metabolite of dopamine and 3-methoxytyrosine is a metabolite of levodopa thus these compounds are proposed to be potential biomarkers of interest. Previous research established a urinary threshold of 4,000 ng/mL for 3-methoxytyramine to monitor misuse of dopaminergic agents. However, there is no equivalent biomarker in plasma. To address this deficiency a rapid protein precipitation method was developed and validated to isolate target compounds from 100 µL equine plasma. A liquid chromatography-high resolution accurate mass (LC-HRAM) method using an IMTAKT Intrada amino acid column provided quantitative analysis of 3-methoxytyrosine (3-MTyr) with lower limit of quantification of 5 ng/mL. Reference population profiling (n = 1129) investigated the expected basal concentrations for raceday samples from equine athletes and showed a right-skewed distribution (skewness = 2.39, kurtosis = 10.65) which resulted from large variation (RSD = 71%) within the data. Logarithmic transformation of the data provided a normal distribution (skewness = 0.26, kurtosis = 3.23) resulting in the proposal of a conservative threshold for plasma 3-MTyr of 1,000 ng/mL at a 99.995% confidence level. A 12-horse administration study of Stalevo® (800 mg L-DOPA, 200 mg carbidopa, 1600 mg entacapone) revealed elevated 3-MTyr concentrations for 24-hours post-administration.
Dried blood spots for erythropoietin analysis: Detection of micro-doses, EPO c.577del variant and comparison with in-competition matching urine samples

Carmel E Heiland,Laurent Martin,Xinmiao Zhou,Lisi Zhang,Magnus Ericsson,Alexandre Marchand

DOI: https://doi.org/10.1002/dta.3596

Abstract:The abuse of recombinant erythropoietin (rEPO) and other erythropoietin (EPO) receptor agonists (ERAs) in sports prompted the need for sensitive detection methods of these substances. Dried blood spot (DBS) samples offer an easy solution for simultaneous collection of blood and urine during a doping control, but sensitivity issues are often presented as a challenge for routine EPO analysis from DBS. Its potential use for detecting rEPO micro-doses and the EPO gene c.577del variant thus needed further demonstration. Here, capillary blood collected from the arm skin of 111 athletes with Tasso-M20 (17.5 μL/spot), collected during professional triathlon competitions, were analysed. Also, venous blood samples from healthy volunteers were used to prepare several spots of 20 μL on Mitra VAMS (from an rEPO micro-dose study) and Whatman filter paper (from an EPO gene variant study). Immunopurification of 2 spots with MAIIA EPO Purification Gel Kit and analysis with sodium N-lauroylsarcosinate polyacrylamide gel electrophoresis (SAR-PAGE)/Western blot resulted in sensitive detection of (1) micro-doses of rEPO from Mitra VAMS, (2) endogenous EPO from Tasso-M20 in all in-competition subjects, and (3) the EPO c.577del variant from Whatman filter paper. Additionally, in-competition endogenous EPO was detected in DBS even when matching urine samples had undetectable EPO. In conclusion, this work demonstrated that DBS can be a useful complementary matrix to urine samples for EPO detection.
Recent Advance in the CE and CE-MS Detection of Recombinant Human Erythropoietin in Doping Control

Nannan Pang,Xia Yang,Yiping Liao,Huwei Liu

DOI: https://doi.org/10.3969/j.issn.1671-7929.2008.07.002

2008-01-01

Abstract:Erythropoietin is a glycoprotein hormone that stimulates erythropoiesis and maintains the red blood cell mass at an optimum level.In the recent years,recombinant human EPO(rhEPO) has been often misused in endurance competition sports.The detection of rhEPO involves a series of analytical challenges due to its relatively short half-life,very low concentration in blood or urine and the high complexity of the mixture of glycoforms.The present review summarized the separation and the detection of rhEPO by capillary electrophoresis(CE) as well as by CE on-line coupled with mass spectrometry(MS) and we also discuss the further development of these techniques.
Rapid and High-Resolution Glycoform Profiling of Recombinant Human Erythropoietin by Capillary Isoelectric Focusing with Whole Column Imaging Detection

Peng Dou,Zhen Liu,Jiangang He,Jing-Juan Xu,Hong-Yuan Chen

DOI: https://doi.org/10.1016/j.chroma.2008.03.001

IF: 4.601

2008-01-01

Journal of Chromatography A

Abstract:Human erythropoietin (hEPO) is a glycoprotein hormone produced primarily by the kidney, which stimulates red blood cell production. Recombinant human erythropoietin (rhEPO), generally produced in Chinese hamster ovary (CHO) cells, can be used as not only a therapeutic protein but also a doping agent in sports. Profiling of EPO glycoforms is a critical means for quality control in pharmaceutical industrial and anti-doping analysis of misuse in sports. However, the existing methods for the analysis of EPO are associated with either time consuming or poor resolution. In this work, a rapid and high-resolution glycoform profiling method was presented based on capillary isoelectric focusing (cIEF) with whole column imaging detection (WCID). Experimental conditions that influence the separation were investigated. Under optimized conditions, rhEPO from three different sources were resolved into distinct populations within 5min with excellent reproducibility. As compared with existing methods, the presented method exhibited the advantages of speed and high resolution. If combined with an effective sample enrichment step and a much more sensitive WCID version, the method can be a potential alternative for the detection of rhEPO misuse in sports.
Assessing EPO stability in urine and comparing recombinant EPO detectability in matched urine, venous serum, and capillary serum following a controlled epoetin alfa administration

Geoffrey D. Miller,Jenna M. Goodrum,Andre K. Crouch,Daniel Eichner

DOI: https://doi.org/10.1002/dta.3736

2024-05-26

Drug Testing and Analysis

Abstract:A single dose of rEPO was administered to twelve healthy volunteers. EPO stability in urine was assessed at different storage conditions. Detectability of rEPO was compared in concurrently collected urine, venous serum, and capillary serum samples. The instability of erythropoietin receptor agonists (ERAs, i.e., EPO) in urine presents a challenge to their detectability in doping control samples; however, this issue is not often seen in blood (serum) samples. With the anti‐doping field beginning to transition into alternative blood collection technologies, it is important to understand recombinant EPO (rEPO) detectability in serum samples collected from one such capillary collection device, the Tasso+ SST. Twelve individuals were administered a single, 40 IU/kg dose of rEPO (epoetin alfa, EPOGEN®). Following administration, matched urine, venous serum, and capillary serum samples were concurrently collected. Urine aliquots were subject to various storage times and temperatures mimicking shipping conditions of doping control urine samples to assess EPO stability, while other urine aliquots, venous serum, and capillary serum aliquots were frozen until analysis to understand rEPO detectability across all three matrices. EPO and rEPO instability was identified in urine collected from 8 of 12 participants, especially in aliquots stored at room temperature and 37°C. In some of these unstable samples, rEPO was still detectable, while in others, no recombinant nor endogenous EPO was detectable and would have resulted in negative sample reports. Analyzing the concurrently collected urine, venous, and capillary serum samples, rEPO detectability was identical across the three matrices. In most cases, rEPO was detectable for at least 168 h post‐administration. Noting greater stability in blood compared with urine, it is recommended that anti‐doping authorities utilize this novel capillary serum collection technology to improve overall ERA detectability in doping control samples.

pharmacology & pharmacy,biochemical research methods,chemistry, analytical
Lipid and Corticosteroid Biomarkers Under the Influence of Bisphosphonates

Kathy Tou,Adam Cawley,Glenys Noble,Jaymie Loy,David Bishop,John Keledjian,Kireesan Sornalingam,Stacey Richards,Shanlin Fu

DOI: https://doi.org/10.1002/dta.3811

2024-10-17

Drug Testing and Analysis

Abstract:The detection of bisphosphonates is important due to the potential integrity and welfare issues associated with use of these substances. Targeted detection of a nitrogenous and non‐nitrogenous bisphosphonate was detected for 8 h and 28 days post‐administration, respectively. With this, the need for complementary indirect detection using lipid and corticosteroid biomarkers was investigated. Putative biomarkers were identified, which are now subject to validation into routine analysis for improved detection capabilities of bisphosphonate misuse in equine plasma. Detecting the use of bisphosphonates (BPs) in equine athletes is of interest to regulators and laboratories due to the threat to welfare issues for the potential to provide analgesic effects and manipulating bone structure. The detection of BPs in biological matrices is challenging due to erratic biological elimination and inconsistent analytical recoveries. Therefore, complementary approaches are needed to provide evidence of their misuse in racehorses. BPs have two sub‐classes: nitrogenous and non‐nitrogenous. This study investigated plasma elimination following administration of one example from each sub‐class, together with changes in endogenous eicosanoid and corticosteroids. Zoledronic acid (ZA) and tiludronic acid (TA) were administered by IV infusion to 8 thoroughbred horses with an 11‐month washout period between each administration. Sample preparation for quantification of BPs by liquid chromatography–tandem mass spectrometry (LC–MS/MS) utilised a two‐step solid phase extraction (SPE) consisting of polymeric reversed‐phase followed by weak anion exchange prior to derivatisation using trimethyl orthoacetate. Endogenous biomarkers were analysed after protein precipitation and SPE with polymeric reversed‐phase prior to liquid chromatography–high resolution mass spectrometry (LC‐HRMS) using data independent acquisition. The LC–MS/MS analysis showed ZA was undetectable after 8 h post‐administration while TA was detected up to the final collection point of 28 days post‐administration. The LC‐HRMS analysis utilised targeted (i.e., prior inclusion list of compounds) approaches to monitor level changes of eicosanoid and corticosteroid biomarkers. Putative biomarkers were identified and now subject to validation for translation into routine sample analysis for improved retrospectivity to detecting BP misuse in equine plasma.

pharmacology & pharmacy,biochemical research methods,chemistry, analytical
Recent Advances in the Detection of Recombinant Human Erythropoiesis and Its Analogs in Doping Control

Yang Xia,Pang Nannan,Liao Yiping,Liu Huwei

2008-01-01

Chinese Journal of Chromatography

Abstract:Recombinant human erythropoietin (rhEPO) is one of hormone dopings. In the recent years, it has been always misused in endurance competition sports. It is extremely difficult to discriminate between the natural endogenous erythropoietin (EPO) and recombinant exogenous hormone because they have identical amino acid sequences, and EPO has a relatively short half-life and very low concentration in blood or urine. In this paper, the research progress on the analysis and detection of rhEPO and its analogs by direct and indirect methods are reviewed. Future direction and prospects of the detection of rhEPO in doping control are discussed based on the research of our group.
Initial development of a rapid, portable, stall-side ELISA for the measurement of equine adrenocorticotropic hormone

Lisa Neufang,Joseph Ramos,Shigetoshi Eda,Bente Flatland,Luca Giori

DOI: https://doi.org/10.1177/10406387241285453

2024-09-25

Abstract:Pituitary pars intermedia dysfunction (PPID) is a neurodegenerative disease of senior horses. Loss of dopaminergic inhibition of the melanotropes of the pars intermedia leads to increased concentrations of pro-opiomelanocortin (POMC)-derived peptides. Diagnosis is challenging due to pre-analytical variables, such as sample storage, handling, and time to analysis. Our objective was to develop an ELISA for ACTH measurement, which could ultimately form the basis for a stall-side equine ACTH test. We selected 2 ACTH-specific monoclonal antibodies, CBL57 and EPR20361-248, based on the recognition of separate epitopes, strong and rapid color change, and minimal background interference, including no cross-reactivity with themselves, each other, and the test reagents. CBL57 was chosen as the detection antibody (or secondary antibody). EPR20361-248, functionalized on superparamagnetic iron oxide beads, was chosen as the capture antibody (or primary antibody) to bind ACTH in plasma. The incorporation of magnetic beads marks the initial stage in establishing a platform that could potentially be utilized in the field, similar to other stall-side tests. The concentrations of antibodies, magnetic beads, and incubation durations were optimized. Our immunoassay detected unglycosylated rat recombinant ACTH. Further studies are ongoing to optimize and validate our assay using equine plasma and serum samples.
Identification and differentiation of somapacitan, a long-acting growth hormone derivative, and recombinant human growth hormone in equine plasma by LC-HRMS for doping control purpose

Yoshibumi Shimizu,Michiko Sugai-Bannai,Kazunobu Saito,Misato Hirano-Kodaira,Gary Ngai-Wa Leung

DOI: https://doi.org/10.1016/j.ghir.2024.101628

IF: 2.125

2024-11-13

Growth Hormone & IGF Research

Abstract:Somapacitan, a long-acting growth hormone derivative, and recombinant human growth hormone (rhGH) are protein-based drugs generally used to treat growth disorders and GH deficiency in humans. Due to their potential to enhance the horse performance, the use of these drugs is prohibited at-all-times by the International Federation of Horseracing Authorities for horseracing and the Fédération Equestre Internationale for equestrian sports. In this study, we developed a test method for the identification and differentiation of somapacitan and rhGH in equine plasma by using liquid chromatography high-resolution mass spectrometry (LC–HRMS). The method involved C4 solid-phase extraction after ammonium sulfate precipitation, followed by chloroform/methanol precipitation, trypsin digestion, and analysis by LC-HRMS. The discriminative identification of somapacitan and rhGH was successfully achieved through the detection of their respective unique T10 peptide fragments. Noteworthy, the T10 peptide fragment of somapacitan was detected with its side chain structure remaining intact. The limit of identification (confirmation) (LOI) was determined to be 5 ng/mL for somapacitan and 2 ng/mL for rhGH in equine plasma, while the limit of detection (LOD) was 5 ng/mL for somapacitan and 1 ng/mL for rhGH. Furthermore, using the peptide fragments T1, T8, and T9 (which are shared between somapacitan and rhGH), the presence of somapacitan in equine plasma could be confirmed with higher sensitivity, achieving down to LOIs of 2 ng/mL and LODs of 1 ng/mL. The method was validated with respect to specificity, identification capability, robustness, precision, and reproducibility, paving the way for the analysis of post-administration samples from our already planned administration trials and future potential positive cases.

cell biology,endocrinology & metabolism
Immuno-magnetic beads-based extraction-capillary zone electrophoresis-deep UV laser-induced fluorescence analysis of erythropoietin

Heye Wang,Peng Dou,Chenchen Lü,Zhen Liu

DOI: https://doi.org/10.1016/j.chroma.2012.02.017

IF: 4.601

2012-01-01

Journal of Chromatography A

Abstract:Erythropoietin (EPO) is an important glycoprotein hormone. Recombinant human EPO (rhEPO) is an important therapeutic drug and can be also used as doping reagent in sports. The analysis of EPO glycoforms in pharmaceutical and sports areas greatly challenges analytical scientists from several aspects, among which sensitive detection and effective and facile sample preparation are two essential issues. Herein, we investigated new possibilities for these two aspects. Deep UV laser-induced fluorescence detection (deep UV-LIF) was established to detect the intrinsic fluorescence of EPO while an immuno-magnetic beads-based extraction (IMBE) was developed to specifically extract EPO glycoforms. Combined with capillary zone electrophoresis (CZE), CZE-deep UV-LIF allows high resolution glycoform profiling with improved sensitivity. The detection sensitivity was improved by one order of magnitude as compared with UV absorbance detection. An additional advantage is that the original glycoform distribution can be completely preserved because no fluorescent labeling is needed. By combining IMBE with CZE-deep UV-LIF, the overall detection sensitivity was 1.5 × 10⁻⁸ mol/L, which was enhanced by two orders of magnitude relative to conventional CZE with UV absorbance detection. It is applicable to the analysis of pharmaceutical preparations of EPO, but the sensitivity is insufficient for the anti-doping analysis of EPO in blood and urine. IMBE can be straightforward and effective approach for sample preparation. However, antibodies with high specificity were the key for application to urine samples because some urinary proteins can severely interfere the immuno-extraction.
Evaluation of microRNA expression in plasma and skeletal muscle of thoroughbred racehorses in training

B A McGivney,M E Griffin,K F Gough,C L McGivney,J A Browne,E W Hill,L M Katz

DOI: https://doi.org/10.1186/s12917-017-1277-z

2017-11-22

Abstract:Background: Circulating miRNAs (ci-miRNAs) are endogenous, non-coding RNAs emerging as potential diagnostic biomarkers. Equine miRNAs have been previously identified including subsets of tissue-specific miRNAs. In order to investigate ci-miRNAs as diagnostic tools, normal patterns of expression for different scenarios including responses to exercise need to be identified. Human studies have demonstrated that many ci-miRNAs are up-regulated following exercise with changes in expression patterns in skeletal muscle. However, technical challenges such as haemolysis impact on accurate plasma ci-miRNA quantification, with haemolysis often occurring naturally in horses following moderate-to-intense exercise. The objectives of this study were to identify plasma ci-miRNA profiles and skeletal muscle miRNAs before and after exercise in Thoroughbreds (Tb), and to evaluate for the presence and effect of haemolysis on plasma ci-miRNA determination. Resting and post-exercise plasma ci-miRNA profiles and haemolysis were evaluated in twenty 3 year-old Tbs in sprint training. Resting and post-exercise skeletal muscle miRNA abundance was evaluated in a second cohort of eleven 2 year-old Tbs just entering sprint training. Haemolysis was further quantified in resting blood samples from twelve Tbs in sprint training. A human plasma panel containing 179 miRNAs was used for profiling, with haemolysis assessed spectrophotometrically. Data was analysed using a paired Student's t-test and Pearson's rank correlation. Results: Plasma ci-miRNA data for 13/20 horses and all skeletal muscle miRNA data passed quality control. From plasma, 52/179 miRNAs were detected at both time-points. Haemolysis levels were greater than the threshold for accurate quantification of ci-miRNAs in 18/25 resting and all post-exercise plasma samples. Positive correlations (P < 0.05) between haemolysis and miRNA abundance were detected for all but 4 miRNAs, so exercise-induced changes in plasma ci-miRNA expression could not be quantified. In skeletal muscle samples, 97/179 miRNAs were detected with 5 miRNAs (miR-21-5p, let-7d-3p, let-7d-5p, miR-30b-5p, miR-30e-5p) differentially expressed (DE, P < 0.05) between time-points. Conclusions: The degree of haemolysis needs to be determined prior to quantifying plasma ci-miRNA expression from horses in high-intensity exercise training. Identification of DE miRNAs in skeletal muscle indicates modification of miRNA expression may contribute to adaptive training responses in Tbs. Using a human plasma panel likely limited detection of equine-specific miRNAs.
Mentoring Diversity. Serving a diverse patient population calls for diverse leadership.

L. Ambrose

2003-09-01

Abstract:
Detection of FG‐4592 and metabolites in equine plasma, urine and hair following oral administration

Charlotte Cutler,Marjaana Viljanto,Polly Taylor,Pamela Hincks,Jocelyn Habershon‐Butcher,Bobby Gray,James Scarth

DOI: https://doi.org/10.1002/dta.3643

2024-01-14

Drug Testing and Analysis

Abstract:Hypoxia‐inducible factor inhibitors, including FG‐4592, are prohibited in sports, and thus identifying the best targets for their detection in doping control is essential. Analysis of equine urine, plasma and hair showed that the parent drug was the best target for detection of oral administration in all three matrices. FG‐4592 is a hypoxia‐inducible factor inhibitor that has been approved for therapeutic use in some countries. This class of compounds can increase the oxygen carrying capacity of the blood and thus have the potential to be used as performance enhancing agents in sports. The purpose of this study was to investigate the detection of FG‐4592 and metabolites in equine plasma and mane hair following a multiple dose oral administration to two Thoroughbred racehorses, to identify the best analytical targets for doping control laboratories. Urine samples were also analysed, and the results compared to previously published urine data. Liquid chromatography‐high resolution mass spectrometry was used for metabolite identification in urine and plasma. Liquid chromatography–tandem mass spectrometry was used for full sample analysis of urine, plasma and hair samples and generation of urine and plasma profiles. FG‐4592 and a mono‐hydroxylated metabolite were detected in plasma. FG‐4592 was detected with the greatest abundance and gave the longest duration of detection, up to 312 h post‐administration, and would be the recommended target in routine doping samples. FG‐4592 was detected in all mane hair samples collected post‐administration, up to 166 days following the final dose, showing extended detection can be achieved with this matrix. To the best of the authors' knowledge, this is the first report of FG‐4592 and metabolites in equine plasma and hair samples. Urine results were consistent with the previously published data, with FG‐4592 offering the best target for detection and longest detection periods.

pharmacology & pharmacy,biochemical research methods,chemistry, analytical
Non-Targeted Detection of Synthetic Oligonucleotides in Equine Serum Using Liquid Chromatography–High-Resolution Mass Spectrometry

Emily Helmes,Jacob Montgomery,Gwendolyne Alarcio,Herra G. Mendoza,Jeffrey A. Blea,Peter A. Beal,Benjamin C. Moeller

DOI: https://doi.org/10.3390/ijms25115752

IF: 5.6

2024-05-26

International Journal of Molecular Sciences

Abstract:There is great concern in equine sport over the potential use of pharmaceutical agents capable of editing the genome or modifying the expression of gene products. Synthetic oligonucleotides are short, single-stranded polynucleotides that represent a class of agents capable of modifying gene expression products with a high potential for abuse in horseracing. As these substances are not covered by most routine anti-doping analytical approaches, they represent an entire class of compounds that are not readily detectable. The nucleotide sequence for each oligonucleotide is highly specific, which makes targeted analysis for these agents problematic. Accordingly, we have developed a non-targeted approach to detect the presence of specific product ions that are not naturally present in ribonucleic acids. Briefly, serum samples were extracted using solid-phase extraction with a mixed-mode cartridge following the disruption of protein interactions to isolate the oligonucleotides. Following the elution and concentration steps, chromatographic separation was achieved utilizing reversed-phase liquid chromatography. Following an introduction to a Thermo Q Exactive HF mass spectrometer using electrospray ionization, analytes were detected utilizing a combination of full-scan, parallel reaction monitoring and all ion fragmentation scan modes. The limits of detection were determined along with the accuracy, precision, stability, recovery, and matrix effects using a representative 13mer oligonucleotide. Following method optimization using the 13mer oligonucleotide, the method was applied to successfully detect the presence of specific product ions in three unique oligonucleotide sequences targeting equine-specific transcripts.

biochemistry & molecular biology,chemistry, multidisciplinary

An analysis of detection bias and proposed corrections in the study of estrogens and endometrial cancer.

Regulation of the stress response by ceramide.

New Transcriptomic Biomarkers for Detection of the Recombinant Human Erythropoietin (rHuEPO) MirCERA in Horses

A hybrid approach for mismatch data reduction in datasets and guide data mining

An enhanced label-free proteomics approach for deep-diving into equine plasma proteome, including the discovery of protein biomarkers for strenuous exercise

Hemicellulose composition of dietary fiber of milled rice and rice bran.

Screening and confirmatory analysis of recombinant human erythropoietin for racing camels' doping control

3-Methoxytyrosine as an indicator of dopaminergic manipulation in equine plasma

Dried blood spots for erythropoietin analysis: Detection of micro-doses, EPO c.577del variant and comparison with in-competition matching urine samples

Recent Advance in the CE and CE-MS Detection of Recombinant Human Erythropoietin in Doping Control

Rapid and High-Resolution Glycoform Profiling of Recombinant Human Erythropoietin by Capillary Isoelectric Focusing with Whole Column Imaging Detection

Assessing EPO stability in urine and comparing recombinant EPO detectability in matched urine, venous serum, and capillary serum following a controlled epoetin alfa administration

Lipid and Corticosteroid Biomarkers Under the Influence of Bisphosphonates

Recent Advances in the Detection of Recombinant Human Erythropoiesis and Its Analogs in Doping Control

Initial development of a rapid, portable, stall-side ELISA for the measurement of equine adrenocorticotropic hormone

Identification and differentiation of somapacitan, a long-acting growth hormone derivative, and recombinant human growth hormone in equine plasma by LC-HRMS for doping control purpose

Immuno-magnetic beads-based extraction-capillary zone electrophoresis-deep UV laser-induced fluorescence analysis of erythropoietin

Evaluation of microRNA expression in plasma and skeletal muscle of thoroughbred racehorses in training

Mentoring Diversity. Serving a diverse patient population calls for diverse leadership.

Detection of FG‐4592 and metabolites in equine plasma, urine and hair following oral administration

Non-Targeted Detection of Synthetic Oligonucleotides in Equine Serum Using Liquid Chromatography–High-Resolution Mass Spectrometry